🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2 Negative

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib NCT07396454Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients NCT06388122n/a1 site📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras… Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer NCT06938724Phase 21 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Omission of local therapies SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases NCT04923542Phase 1, Phase 22 sites📍 Tampa📍 Columbus H. Lee Moffitt Cancer Center and Research Institute · Tests: Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer. NCT06902545n/a15 sites📍 Goyang-si📍 Suwon📍 Suwon Astellas Pharma Korea, Inc. · Tests: zolbetuximab Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532NA49 sites📍 Phoenix📍 Scottsdale📍 Tucson Natera, Inc. · Tests: ctDNA-Guided Treatment Strategy Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer NCT06837792Phase 21 site📍 Seoul Yonsei University · Tests: Experimental treatment arm, Control treatment arm A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer NCT07112053Phase 21 site📍 Seattle University of Washington · Tests: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4… SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site📍 Shanghai Fudan University · Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer NCT07276880Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer NCT05744687Phase 2, Phase 39 sites📍 Fuzhou📍 Guangzhou📍 Guiyang Shanghai Pharmaceuticals Holding Co., Ltd · Tests: SPH4336 Tablets 400mg, SPH4336 Tablets Placebo Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631Phase 19 sites📍 Princeton📍 Montreal📍 Odense C Novartis Pharmaceuticals · Tests: 68Ga-NNS309, 177Lu-DFC413 Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach NCT07178340Phase 21 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules a… Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies NCT07211178n/a16 sites📍 Birmingham📍 Whittier📍 Weston Tempus AI · Tests: There are no interventions in this observational study. Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy NCT06498154Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Abemaciclib, Radiation Therapy A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites📍 Bengbu📍 Hefei📍 Hefei Genor Biopharma Co., Ltd. · Tests: GB491 combined with Letrozole, Placebo combined with Letrozole Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584Phase 21 site📍 Orange University of California, Irvine · Tests: Fulvestrant, Anastrozole, Abemaciclib PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer NCT06637150Phase 31 site📍 Shanghai Fudan University · Tests: Dalpicilib, endocrine therapy Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study NCT07311577Phase 22 sites📍 Nanjing📍 Nanjing Jiangsu Cancer Institute & Hospital · Tests: RC48+Carboplatin+Bevacizumab A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer NCT06508216Phase 1, Phase 21 site📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Dato-DXd, Durvalumab Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site📍 Shanghai Wenjin Yin · Tests: QL1706, CDK4/6 inhibitor, Fulvestrant
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy